Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page
- Check6 days agoChange DetectedVersion 57 was added on 2026-05-01, and the record now shows a QC status of Has Not Concluded. The history presents expanded content areas such as Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status, and related document sections.SummaryDifference1.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page’s build/release “Revision” indicator was updated from v3.5.2 to v3.5.3, reflecting a maintenance/software version bump rather than a change to the displayed trial record history content.SummaryDifference0.1%

- Check27 days agoChange DetectedThe history now shows Results Submitted and Revision: v3.5.2, replacing No Results Posted and Revision: v3.5.0.SummaryDifference0.1%

- Check56 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the history list.SummaryDifference0.1%

- Check63 days agoChange DetectedThe new screenshot shows Revision: v3.4.3 in the history, replacing Revision: v3.4.2. This is a small metadata update documenting the latest version.SummaryDifference0.1%

- Check85 days agoChange DetectedThe screenshots depict the same history page with only minor UI/organizational changes and a new version entry added. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.